There may be opportunities further down the road for Bisantrene to synergies with CAR-T, not just chemo drugs to utilise the FTO benefits.
Triangle report actually mentioned a drop in usage of current standard of care as new therapies are developed as part of the risk & cost adjustment. Think it also expected uptake of new therapies to play out over quite a few years past 2030.
General Comments / Chat, page-8443
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.55 | $189.9K | 121.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1316 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 34961 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |